Here’s what you need to know:
transcript
transcript
New York City Postpones Vaccine Appointments Ahead of Storm
Mayor Bill de Blasio said the city would postpone Covid-19 vaccinations scheduled for Monday and suspend in-person learning for the day after winter storm conditions were forecast for the area.
-
“For Monday, we are not going to have in-person school. We will pivot to remote learning for all our students. So no school in-person on Monday — canceled now. We will have an update tomorrow about Tuesday. Right now we do not have a decision for Tuesday yet. We have to see more about how this storm develops. Vaccine sites, and again, we want to get everyone vaccinated. We’re going be talking about that later, There’s such urgency, But there’s also going to be tremendous difficulty and danger getting around Monday. Last thing we want to do is urge our seniors to come out in the middle of a storm like this. It doesn’t make sense. So we’re rescheduling Monday appointments for vaccine. They’ll be postponed. The Monday vaccine appointments will be postponed. We’ll get them done as quickly as humanly possible. But it’s just not going to be safe out there on Monday. The Tuesday vaccine appointments, right now we’re hoping to get those on time. We’re going to have more information on that as we go along.”
Vaccine sites in the New York metro area are closed Monday because of a looming winter storm that is expected to dump up to 16 inches of snow on the region.
A powerful winter storm sweeping up the Atlantic Coast was also disrupting vaccinations in Washington, D.C., Philadelphia, New Jersey and elsewhere.
At a news conference on Sunday, Mayor Bill de Blasio said he did not want older New Yorkers on the road traveling to vaccine appointments, warning of blizzard-like conditions with gusty winds. Vaccinations scheduled for Tuesday in New York City have not been canceled, for now, Mr. de Blasio said.
The storm will temporarily derail a vaccine rollout in New York City that has been plagued with inadequate supply, buggy sign-up systems and confusion over the state’s strict eligibility guidelines. The vaccine is available to residents 65 and older as well as a wide range of workers designated “essential.”
About 800,000 doses have been administered so far in the city, Mr. de Blasio said.
Vaccine appointments at several sites in the region — the Javits Center in Manhattan, the Aqueduct Racetrack in Queens, a drive-through site at Jones Beach in Long Island, SUNY Stony Brook and the Westchester County Center — will be rescheduled for this week, according to a statement from Melissa DeRosa, a top aide to Gov. Andrew Cuomo. “We ask all New Yorkers to monitor the weather and stay off the roads tomorrow so our crews and first responders can safely do their jobs,” she said.
In the Philadelphia area, city-run testing and vaccine sites will be closed on Monday. Rhode Island, Connecticut, New Jersey and parts of the D.C., Maryland and Virginia areas were following suit. Some areas away from the center of the storm were expected to remain open for vaccinations, including parts of Massachusetts and upstate New York.
In Oregon, a storm on Tuesday led one group of health officials transporting vaccines near their expiration to offer them to drivers stuck on the side of the road.
The rollout in New York City has also been hampered by distribution issues and stark racial disparities, with Black and Latino residents receiving far fewer doses than white residents, according to Mr. de Blasio.
The city’s demographic data was incomplete, but the numbers so far were striking: Of nearly 300,000 city residents who received one dose and whose race was recorded, about 48 percent were white, 15 percent were Latino, 15 percent were Asian and 11 percent were Black. Latino and Black residents were underrepresented: The city’s population is roughly 29 percent Latino and 24 percent Black.
An attempt to bring more vaccination kits to underserved communities in Brooklyn and the Bronx, including at churches and public housing sites, was also put on delay for the storm this week, as six pop-up sites in the two boroughs were rescheduled to Wednesday, Ms. DeRosa said.
Vaccinations in the United States are slowly picking up speed as the Biden administration pushes to accelerate inoculations and blunt the spread of more contagious virus variants.
The United States has administered about 30 million doses, and, as of Sunday, is averaging more than 1.3 million doses administered over the past seven days, compared with an average of less than one million per day two weeks earlier, according to a New York Times vaccine tracker.
President Biden, under pressure to speed up coronavirus vaccinations, has recently suggested the nation could soon reach an average of 1.5 million shots a day.
But just as there are signs of progress, another problem has taken root: the spread of the variants, which scientists warn must be contained before they become dominant. Several hundred cases of the more contagious variant discovered in Britain, which experts have said could be the dominant form in the United States by March, have already been confirmed.
The country has also recorded its first two cases of the variant spreading rapidly in South Africa, which has proved to reduce the effectiveness of vaccines.
“If we didn’t have these variants looming,” we would be in a good place, said Dr. Peter Hotez, a vaccine scientist and pediatrician at Baylor College of Medicine in Houston. If those variants take over by spring, “as many of us are predicting,” he said, “it changes everything. Now, we really have to vaccinate the American population by late spring, early summer.”
Two key challenges in the weeks ahead are “increasing the supply of vaccines” and “speeding up the time it takes to administer them,” Andy Slavitt, a White House adviser, said in a news briefing on Friday. Many experts have pushed for bringing other vaccine options out and releasing the first doses more widely.
The most effective state programs, said Dr. Ashish Jha, the dean of the Brown University School of Public Health, are “very simple, age-based, not a lot of complex rules. They focus on getting the vaccines out.”
Here is a snapshot of how five of the best-performing states are doing:
-
West Virginia has given at least one dose to 10.7 percent of its population, second only to Alaska, and leads the nation in the percentage of its population that has received two doses (3.7 percent). Early on, the state got a head start because it opted out of a federal program to vaccinate people in nursing homes and other long-term care facilities. While other states chose the federal plan, which teamed with Walgreens and CVS, officials decided the idea made little sense in West Virginia, where many communities are miles from the nearest chain store, and about half of pharmacies are independently owned. Instead the state created a network of pharmacies, pairing them with about 200 long-term care facilities.
-
According to health officials in Alaska, there are several reasons behind the state’s relatively high vaccination rate, The Anchorage Daily News has reported. Those factors include: the state’s having received a high number of doses through the Indian Health Service; the decision to receive doses monthly, versus weekly, as most states do; and declining virus caseloads, which has allowed health care workers to focus on inoculations. The state has vaccinated 13 percent of its population, according to a Times database.
-
North Dakota has used 91 percent of the vaccines distributed to the state, according to the Times vaccine tracker. It is the only state above 90 percent; more populous states like California (58 percent) and New York (64 percent) have used less, proportionally. North Dakota was among the first states to lower the minimum age eligible for vaccination, from 75 to 65.
-
In a recent interview with the American Medical Association, health officials in New Mexico attributed part of the state’s success to its “data-oriented and science-oriented” governor, Michelle Lujan Grisham, and to an app that allowed easy registration and close coordination among hospitals and providers. The state has given 9.8 percent of residents at least one shot, and has used 83 percent of its doses.
-
Connecticut got mass vaccination sites up and running early, and uses an inventory system that allocates unused doses to places that need them. But older residents have complained about long waits.
The police in China have broken up a counterfeiting ring that they say manufactured and sold more than 3,000 fake coronavirus vaccines across the country, Xinhua, China’s state-run news agency, reported on Monday.
More than 80 suspects have been arrested in the provinces of Jiangsu and Shandong, in the city of Beijing and in other places, Xinhua said.
According to the agency, the police said that the main suspect, a person surnamed Kong, had been injecting saline into vials and selling them as coronavirus vaccines since September.
“The manufacturing and selling of fake vaccines are crimes of a vile nature and can cause serious harm,” Xinhua said. It added that the police were urging members of the public to get vaccinated “through the regular channels to avoid being deceived.”
The arrests began with an order from the Ministry of Public Security to crack down on vaccine-related crimes. Late last year, the demand for Covid-19 vaccines in China was so high that it inspired a cottage industry of scalpers who charged as much as $1,500 for an appointment.
The government is also wary of having to deal with the possible political fallout from another vaccine scandal. In recent years, reports that Chinese companies have fabricated data about their vaccines or made inoculations that have sickened infants have rattled public confidence in domestic vaccines, even though they have been proved safe. Many well-off parents shun them in favor of their Western counterparts.
Unlike many other countries, China has not signaled that it plans to vaccinate its entire population of 1.4 billion people. It has vaccinated about 24 million people, mostly essential workers, about half of its target of inoculating 50 million people by Feb. 12, the start of the Lunar New Year.
BERLIN — As Germany’s leaders gather in Berlin to discuss the lagging vaccination rollout in the country and across the European Union, the bloc got some good news Monday morning when the pharmaceutical company BioNTech announced that it would make 75 million extra doses available in coming months.
BioNTech, a German company, helped developed the first Covid vaccine to be approved in the European Union. It had previously come under fire for admitting, just weeks after the beginning of the bloc’s vaccination drive, that it could temporarily deliver fewer doses than promised because of an upgrade at a production facility in Puurs, Belgium.
But the company will soon be producing shots at 13 different locations, including a new site in Marburg, Germany, Sierk Poetting, BioNTech’s chief operating officer, said in a statement on Monday.
And the British-Swedish pharmaceutical company AstraZeneca, which has also come under criticism for not fulfilling European orders in a timely fashion, has agreed to deliver 40 million more doses by June, Ursula von der Leyen, the president of the European Commission, announced in a tweet on Sunday. That would be nine million more than originally planned.
At a virtual meeting on Monday to address criticism over the slow start of the rollout, Chancellor Angela Merkel of Germany was set to speak with national ministers, state governors, and representatives from the pharmaceutical industry.
Since vaccines began to receive approval in the European Union, starting at the end of December, about 1.9 million people in Germany, or around 2.2 percent of the population, have received at least one vaccination dose, according to the health authorities there. In the United States, more than 30 million people, or about 7.6 percent of the population, have received at least one shot.
The past few weeks in the United States have been the deadliest of the coronavirus pandemic, and residents in a majority of counties remain at an extremely high risk of contracting the virus. At the same time, transmission seems to be slowing throughout the country, with the number of new average cases 40 percent lower on Jan. 29 than at the U.S. peak three weeks earlier.
Other indicators reinforce the current downward trend in cases. Hospitalizations are down significantly from record highs in early January. The number of tests per day has also decreased, which can obscure the virus’s true toll, but the positivity rate of those tests has also gone down, indicating that the slowed spread is real.
Still, the average reported daily death rate over the past seven days remains above 3,000, compared with less than 1,000 per day in September and October.
Experts say the decrease could mark a turning point in the outbreak after months of ever-higher caseloads. But new, more contagious variants threaten to upend progress and could even send case rates to a new high if they take hold, especially if the national vaccine rollout faces hurdles.
During January, the pandemic’s deadliest month, Laredo, Texas, held the bleak distinction of having one of the most severe outbreaks of any city in the United States. The death toll in the overwhelmingly Latino city of 277,000 now stands at more than 630 — including at least 126 in January alone.
When the virus made its way to the borderlands almost a year ago, Dr. Ricardo Cigarroa could have just hunkered down. He could have focused on his profitable cardiology practice, which has 80 employees. He could have kept quiet.
Instead, Dr. Cigarroa has become a top crusader and the de facto authority on the pandemic along this stretch of the U.S.-Mexico border.
On regional television stations, he calmly explains, in both English and Spanish, how the virus is evolving. Known for making Covid-19 house calls around Laredo in his old Toyota Tacoma pickup, he is interviewed so often that Texas Monthly called him “The Dr. Fauci of South Texas,” comparing him to Dr. Anthony S. Fauci, the country’s top infectious disease expert — though Dr. Cigarroa holds no official government portfolio.
Lately, Dr. Cigarroa has been losing his patience.
Looking exhausted in a video posted on Facebook, he blasted political leaders for allowing the virus to rampage through this part of South Texas. Dr. Cigarroa singled out Gov. Greg Abbott, a Republican, for refusing to allow Laredo to impose stricter mitigation measures.
“To the governor: It’s OK to swallow your pride,” Dr. Cigarroa said, stunning some viewers with a warning that the virus could kill 1 in 250 Laredoans by midyear. “It’s OK to say that you’re not going to do it, and then do it to save lives.”
Pleading with the people of Laredo to consider civil disobedience in the form of staying home from work if politicians fail to act, he added, “The only thing that will save lives at this point will be staying home and shutting down the city.”
As Democrats and Republicans spent months last fall arguing over how to rescue the economy, one provision drew widespread support from lawmakers: reviving the Paycheck Protection Program, the government’s marquee effort to help small businesses weather the pandemic.
The Senate Republican leader, Mitch McConnell of Kentucky, called the lending program “a bipartisan slam dunk.” House Democrats included an extension and expansion of the program in aid packages in the summer and the fall. And Treasury economists said in December that the program might have saved nearly 19 million jobs.
Yet there is dissent from one notable contingent: Academic economists who have studied the program have concluded that it has saved relatively few jobs and that, at a cost of more than half a trillion dollars, it has been far less efficient than other government efforts to help the economy.
“A very large chunk of the benefit went to a very small share of the firms, and those were probably the firms least in need,” said David Autor, an M.I.T. economist who led one study.
The divergence in views over the program’s economic payoff stems in part from ambiguity about its goals: saving jobs or saving businesses.
Using different methodology than the Treasury economists, Mr. Autor says the Paycheck Protection Program saved 1.4 million to 3.2 million jobs. Other researchers have offered broadly similar estimates.
Given the program’s cost, saving jobs on that scale doesn’t necessarily qualify as a success. Unemployment benefits also provide income, at far less expense, and programs like food assistance and aid to state and local governments pack a larger economic punch, according to many assessments.
And because the paycheck program was designed to reach as many businesses as possible, much of the money went to companies that were at little risk of laying off workers, or that would have brought them back quickly even without the help.
Many policy experts on Wall Street and in Washington — as well as businesses and banks on Main Streets across the country — say the program’s merits should be assessed instead on what it did to save businesses. On that basis, they say, it helped prevent a greater calamity and fostered economic healing.
Japan’s biggest cities are under a state of emergency as coronavirus deaths rise, even while the country tries to convince the world it can safely hold the Summer Olympics. South Korea is prohibiting gatherings of five or more people to keep a recent surge under control. Hong Kong imposed stringent lockdowns on some of its poorest neighborhoods to stop an uptick.
And yet none of these places have begun to carry out the only solution with any hope of putting the pandemic behind them: vaccinations.
While the United States and most nations in Europe, as well as China and India, have begun inoculating their populations, Japan, South Korea and Hong Kong have stood out by proceeding much more slowly.
Japan will not even begin to vaccinate medical workers until the end of February. The same is true in South Korea, and those over 65 will not start receiving inoculations until May. Hong Kong, a semiautonomous territory of China, will begin vaccinating “high risk” groups in the middle of February.
To a certain extent, the three East Asian economic powerhouses have the luxury of time. Despite recent increases in infections, they have not experienced the kinds of outbreaks that have devastated the United States or Britain.
The delays, which come as more contagious and perhaps deadlier variants of the virus are emerging around the globe, could hamper these governments’ efforts to protect the public and restore normalcy for their weary populations.
But postponement also offers opportunities. The laggards can take the time to learn from the troubled rollouts in the United States and Europe.
By moving more deliberately, the East Asian governments may also be able to alleviate some concerns among the public about the remarkable speed with which the vaccines have been created. In Japan and South Korea, polls show that many people are reluctant to get vaccinated right away.
Supply, too, may restrain the speed of the rollout. While Hong Kong approved Pfizer’s vaccine in January, neither Japan nor South Korea has approved any yet.
In theory, Japan has a more urgent deadline. The government is insisting that it will proceed with the Olympics despite intensifying questions about the feasibility of doing so. The Games, which were originally scheduled for 2020 in Tokyo but postponed to this summer, are scheduled to open on July 23.
